POS1200 DIFFERENCES BETWEEN THE FIRST AND THE SECOND WAVE OF SARS-COV-2 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES IN ARGENTINA: DATA FROM THE SAR-COVID REGISTRY
Authors: A. Bertoli, L. Muñoz, M. J. López Pérez, L. Sanchez Freytes, M. S. Castaño, V. Saurit, G. Berbotto, G. Alle, M. Severina, R. Nieto, F. Maldonado, M. Pera, A. K. Cogo, A. R. Baños, F. Vivero, D. A. Pereira, M. Cosatti, V. Savio, R. Perez Alamino, M. A. Medina, M. Schmid, F. Risueño, M. I. Quaglia, G. P. Pendon, L. Casalla, M. Delavega, M. A. Lazaro, P. Finucci, J. Morbiducci, C. Romeo, N. Cucchiaro, S. Moyano, T. Barbich, S. M. Conti, C. Goizueta, E. R. Tralice, C. Maldini, J. Rebak, R. Gallo, P. Maid, J. L. Velasco Zamora, N. Lloves Schenone, S. Porta, N. S. Morales, M. P. Diaz, M. Viola, E. Buschiazzo, G. Gómez, K. Roberts, R. Quintana, C. A. Isnardi, G. Pons-Estel, C. E. Matellan
Journal: Annals of the Rheumatic Diseases (2022)

Background In Argentina we have witnessed two COVID 19 waves between 2020 and 2021. The first wave occurred during the spring of 2020 and it was related to the wild type of the virus, the second occurred during the fall/winter of 2021 when the gamma variant showed a clear predominance. During the first wave, patient with rheumatic diseases showed a higher frequency of hospitalization and mortality (4% vs 0.26%) when compared to the general population 1 ; at that time, however, vaccination was not yet available. Objectives To compare sociodemographic and disease characteristics, course and outcomes of SARS-CoV-2 infection in patients with immune-mediated/autoinflammatory diseases (IMADs) during the first and second waves in Argentina. Methods SAR-COVID is a national, multicenter, longitudinal and observational registry, in which patients ≥18 years of age, with a diagnosis of a rheumatic disease who had confirmed SARS-CoV-2 infection (RT-PCR or positive serology) were consecutively included since August 2020. For the purpose of this report, only patients with IMADs who had SARS-CoV-2 infection during the first wave (defined as cases occurred between March 2020 and March 2021) and the second wave (cases occurred between April and August 2021) were examined. Sociodemographic characteristics, disease diagnosis and activity, comorbidities, immunosuppressive treatment and COVID 19 clinical characteristics, complications and outcomes: hospitalization, intensive care unit (ICU) admission, use of mechanical ventilation and death were compared among groups. Descriptive statistical analysis was performed. Variables were compared with Chi squared test and Student T test or Mann Whitney test. Multivariable logistic regression models with forward and backward selection method, using hospitalization, ICU admission and death as dependent variables were carried out. Results A total of 1777 patients were included, 1342 from the first wave and 435 of the second one. Patients had a mean (SD) age of 50.7 (14.2) years and 81% were female. Both groups of patients were similar in terms of socio-demographic features, disease diagnosis, disease activity, the use of glucocorticoids ≥ 10 mg/day and the immunosuppressive drugs (Table 1 below). Patients infected during the first wave have higher frequency of comorbidities (49% vs 41%; p= 0.004). Hospitalizations due to COVID 19 (31% vs 20%; p &lt;0.001) and ICU admissions (9% vs 5%; p= 0.009) were higher during the first wave. No differences in the use of mechanical ventilation (16% vs 16%; p= 0.97) nor in the mortality rate (5% vs 4%; p= 0.41) were observed. In the multivariable analysis, after adjusting for demographics, clinical features and immunosuppressive treatment, patients infected during the second wave were 40% less likely to be hospitalized (OR= 0.6, IC95% 0.4-0.8) and to be admitted to the ICU (OR= 0.6, IC95% 0.3-0.9). Table 1. Variable (% or Mean – SD) First wave(n=1342) Second wave(n=435) p Value Female gender 81 80 0.7 Age (years) 51.0 (14.5) 50.0 (13.3) 0.2 Disease diagnosis Rheumatoid arthritis 46 46 1 Ankylosing spondylitis 10 11 0.8 Systemic lupus erythematosus 17 185 0.9 Systemic Scleroderma 5 5 1 Sjögren´s syndrome 6 5 0.7 Inflammatory myopathies 3 3 0.5 Vasculitis 4 3 0.4 Disease activity High 4 3 0.5 Use of immune modulators DMARDcs 53 56 0.2 DMARDts 4 6 0.1 DMARDb 82 82 1 Use of glucocorticoids ≥10 mg 12 12 0.9 Comorbidities 49 41 0.004 Conclusion The impact of COVID 19 in Argentina, in terms of mortality in patients with IMADs was still higher compared to the general population during the second wave. However, the frequency of hospitalizations and ICU admissions was lower. These findings could be explained by the introduction of the SARS COV 2 vaccination and, probably, by the cumulative knowledge and management improvement of this infection among physicians. References [1]Isnardi CA et al. Epidemiology and outcomes of patients with rheumatic diseases and SARS-COV-2 infection: data from the argentinean SAR-COVID Registry. Ann Rheum Dis, 2021, suppl 1, 887. Disclosure of Interests None declared